Breast Cancer
Conference Coverage
Chemo avoidance pays off for some women with HER2+ early BC
Almost all patients who skipped chemotherapy avoided invasive disease/death at 3 years.
Conference Coverage
Breast cancer: Meta-analysis supports ovarian suppression/ablation
Controlling estrogen seems to give premenopausal women a lifespan boost, but strategy remains uncommon.
Feature
How a medical recoding may limit cancer patients’ options for breast reconstruction
The Centers for Medicare & Medicaid Services plans to reexamine how doctors are paid for a type of breast reconstruction known as DIEP flap....
From the Journals
Lack of paid sick leave is a barrier to cancer screening
For those with paid sick leave mandates, screening rates are higher.
Conference Coverage
Circulating tumor DNA may predict poor prognosis in breast cancer
Detection of ctDNA at any time point was associated with worse overall and disease-free survival in early breast cancer patients.
Conference Coverage
Breast cancer outcomes are worse for Black men
Black Americans are more likely to be diagnosed at older ages and to die from the disease.
Conference Coverage
Breast cancer survivors need a comprehensive care plan, says doctor
Survivor care for cancer patients should address physical and psychological symptoms through an integrated model, expert says.
Conference Coverage
PARP inhibitors and breast cancer: Questions remain about wider use
Oncologists are still trying to understand the best drug targets and the value of combo treatments.
Conference Coverage
Genomic assay changes minds on HER2+ BC treatment
In a small study, 56% of oncologists revised plans after getting results of HER2DX tests.
Conference Coverage
Atezolizumab is associated with enhanced response in triple-negative breast cancer
The addition of atezolizumab to chemotherapy yielded higher pCR than chemotherapy alone.
From the Journals
Risk for breast cancer reduced after bariatric surgery
“The importance of this study is that it shows that weight loss in midlife can reduce breast cancer risk back to or even below the risk of similar...